Molecular Molecules has developed a drug development factory that is a first of its kind. With the cost of drug discovery and development at more than a billion dollars and taking 10-15 years to reach the market, we knew that to become the world's next multi-billion dollar drug company we would need a tool to help us. We are now announcing that our technical team has developed the ultimate platform for screening, discovering, testing (pre-clinical and clinical) and manufacturing each drug automatically. Like an automated assembly line, this system takes up more than 5,000 square feet of space supported by only 10 scientists and technicians 24/7. Our proprietary platform has been installed and ready for production as of June 10th, 2012, and has already discovered a drug for PCFS.
Our company is ready to bring massive change to the pharmaceutical industry - but we are also ready to work with our partners to be sure we share the technology that will be responsible for this change. Our mission is to bring strong value to our shareholders, as well as high impact, cost effective products to our markets. Even though we won't be playing by the silly regulatory rules everyone else is stuck with, we will certainly use high standards to assure high quality.
We recognize our initial claims will be held with suspicion and skepticism. We would be skeptical as well. However, with results coming in from our early introduction of our PCFS drug to pharmaceutical executives we (and the executives) could not be more pleased. When we have enough data to report to the market we will keep you posted (click here for instant email or text updates)
Our company is ready to bring massive change to the pharmaceutical industry - but we are also ready to work with our partners to be sure we share the technology that will be responsible for this change. Our mission is to bring strong value to our shareholders, as well as high impact, cost effective products to our markets. Even though we won't be playing by the silly regulatory rules everyone else is stuck with, we will certainly use high standards to assure high quality.
We recognize our initial claims will be held with suspicion and skepticism. We would be skeptical as well. However, with results coming in from our early introduction of our PCFS drug to pharmaceutical executives we (and the executives) could not be more pleased. When we have enough data to report to the market we will keep you posted (click here for instant email or text updates)